BioNTech (NASDAQ:BNTX) and OncoC4 have had a partial clinical hold placed by the FDA on a Phase 3 study for their drug ...

BioNTech (NASDAQ:BNTX) shares fell Friday after the company said it had been informed by partner OncoC4 that FDA placed ...

The FDA has implemented a partial hold on a phase 3 non-small cell lung cancer trial run by BioNTech and OncoC4 after seeing ...

The mRNA Revolution When the COVID-19 pandemic struck, the world's medical community initially prepared for a disaster of the scale of the Spanish Flu, which struck during WW1 and killed 50 million ...

mRNA vaccines, pivotal in the fight against COVID-19, are now emerging as a promising innovation in cancer treatment. As ...

Discover why the stock prices of mRNA therapy creators BioNTech and Moderna have plummeted and whether they are still worth ...

As companies roll out data showing the power and improved safety profile of antibodies that target two antigens, analysts say ...

BioNTech (Nasdaq: BNTX) and partner USA-based OncoC4 understand that the partial clinical hold in the ongoing Phase III trial ...

BioNTech has launched global clinical trials for BNT116, an mRNA vaccine designed to treat non-small cell lung cancer. Utilizing the same mRNA technology as Covid-19 vaccines, BNT116 aims to prime ...

Goshen Center for Cancer Care is recognizing the completion of 50 procedures utilizing cutting-edge robotic technology to provide a less invasive option to biopsy lung lesions. The Galaxy System is a ...

Truist Financial Corp lowered its position in shares of BioNTech SE (NASDAQ:BNTX – Free Report) by 4.1% in the second quarter ...